Study #2024-1083
A phase 1a/1b study of LY4052031, an antibody-drug conjugate targeting Nectin-4, in participants with advanced or metastatic urothelial carcinoma or other solid tumors
MD Anderson Study Status
Enrolling
Treatment Agent
Description
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Study phase:
Physician name:
Arlene Siefker-Radtke
Department:
Genitourinary Medical Oncology
For general questions about clinical trials:
1-888-448-0874
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.